HotSpot Therapeutics Reveals Groundbreaking Preclinical Data on IRF5 Inhibition at FOCIS 2025 HotSpot Therapeutics has presented innovative preclinical results for their IRF5 program at FOCIS 2025, showcasing potential for autoimmune disease treatments.

HotSpot Therapeutics Reveals Groundbreaking Preclinical Data on IRF5 Inhibition at FOCIS 2025 #United_States #Boston #HotSpot_Therapeutics #IRF5_inhibitors #Smart_Allostery